<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-386X</journal-id>
<journal-title><![CDATA[Revista Facultad Nacional de Salud Pública]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Fac. Nac. Salud Pública]]></abbrev-journal-title>
<issn>0120-386X</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Antioquia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-386X2020000100101</article-id>
<article-id pub-id-type="doi">10.17533/udea.rfnsp.v38n1e332273</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Estrategias para promover el acceso a medicamentos de interés en salud pública: revisión estructurada de la literatura]]></article-title>
<article-title xml:lang="en"><![CDATA[Strategies to promote access to medicines of interest in public health: structured review of the literature]]></article-title>
<article-title xml:lang="pt"><![CDATA[Estratégias para promover o acesso a medicamentos de interesse em saúde pública: revisão estruturada da literatura]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ledezma-Morales]]></surname>
<given-names><![CDATA[Mónica]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vargas-Peláez]]></surname>
<given-names><![CDATA[Claudia Marcela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rossi-Buenaventura]]></surname>
<given-names><![CDATA[Francisco Augusto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Fundación IFARMA  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Fundación IFARMA  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>01</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>01</month>
<year>2020</year>
</pub-date>
<volume>38</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-386X2020000100101&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-386X2020000100101&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-386X2020000100101&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Identificar estrategias orientadas a favorecer el acceso a medicamentos de interés en salud pública, de alto costo o protegidos por patentes, posiblemente aplicables al contexto colombiano.  Metodología:  revisión estructurada en PubMed/Medline, utilizando los términos MeSH: &#8220;health services accessibility&#8221;, &#8220;pharmaceutical preparations&#8221;, &#8220;policy&#8221;, con filtros para artículos publicados en inglés y español, entre 2012 y 2017. Se incluyeron aquellos con información sobre estrategias o políticas que favorecieran el acceso a medicamentos de interés en salud pública de alto costo o protegidos por patentes. Las estrategias identificadas fueron agrupadas acorde con las cinco dimensiones del acceso a la atención en salud y medicamentos definidas por la Organización Mundial de la Salud: disponibilidad, asequibilidad, accesibilidad, aceptabilidad y calidad.  Resultados:  Se identificaron 62 artículos, de los cuales se incluyeron 18 y se consideraron 5 referencias adicionales. Se reconocieron 30 estrategias, distribuidas y clasificadas según las dimensiones del acceso: disponibilidad y asequibilidad, 15; accesibilidad, 6; aceptabilidad, 6; calidad, 2; estrategia transversal, 1.  Conclusiones:  Se identificaron estrategias claves para favorecer el acceso a medicamentos de interés en salud pública de alto costo o protegidos por patentes, dentro de las que se encuentran las negociaciones centralizadas de precios; el apoyo financiero público para la investigación, desarrollo y producción nacional de medicamentos genéricos; la aplicación de las flexibilidades del acuerdo sobre los &#8220;Aspectos de los derechos de propiedad intelectual relacionados con el comercio&#8221; y la implementación de programas de asistencia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective:  To identify strategies aimed to improve access to medicines of interest in public health with high cost or protected with patents, possibly applicable to the Colombian contextTo identify strategies aimed at promoting access to high-cost or patent-protected medicines of interest in public health, possibly applicable to the Colombian context..  Methodology:  structured review in PubMed/Medline, using the MeSH terms: &#8220;health services accessibility&#8221;, &#8220;pharmaceutical preparations&#8221;, &#8220;policy&#8221;, with filters for articles published in English and Spanish, between 2012 and 2017. Studies with information on strategies or policies that favored access to high-cost or patent-protected drugs of interest in public health were included. The strategies identified were grouped according to the five dimensions of access to health care and medicines defined by the World Health Organization: availability, affordability, accessibility, acceptability and quality.  Results:  62 articles were identified, of which 18 were included, and 5 additional references were considered. 30 strategies were recognised, distributed and classified according to the dimensions of access: availability and affordability, 15; accessibility, 6; acceptability, 6; quality, 2; cross-cutting strategy, 1.  Conclusions:  Key strategies were identified to favor access to high-cost or patent-protected medicines of interest in public health, including centralized price negotiations; public financial support for national research, development and production of generic medicines; the application of the flexibilities of the agreement on &#8220;Aspects of intellectual property rights related to trade&#8221; and the implementation of care programs.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Objetivo:  Identificar estratégias destinadas a favorecer o acesso a medicamentos de interesse em saúde pública, de alto custo ou protegidos por patentes, possivelmente aplicáveis ao contexto colombiano.  Metodologia:  Revisão estruturada no PubMed/Medline, usando os termos MeSH: &#8220;health services accessibility&#8221;, &#8220;pharmaceutical preparations&#8221;, &#8220;policy&#8221;, com filtros para artigos publicados em inglês e espanhol, entre 2012 e 2017. Foram incluídos aqueles com informações sobre estratégias ou políticas que favoreciam o acesso a medicamentos de interesse em saúde pública de alto custo ou protegidos por patentes. As estratégias identificadas foram agrupadas de acordo com as cinco dimensões de acesso aos cuidados de saúde e medicamentos definidas pela Organização Mundial da Saúde: disponibilidade, alcançabilidade, acessibilidade, aceitabilidade e qualidade.  Resultados:  Foram identificados 62 artigos, dos quais 18 foram incluídos e 5 referências adicionais foram consideradas. 30 estratégias foram identificadas, distribuídas e classificadas de acordo com as dimensões do acesso: disponibilidade e alcançabilidade, 15; acessibilidade, 6; aceitabilidade, 6; qualidade 2; estratégia transversal, 1.  Conclusões:  Foram identificadas estratégias-chave para favorecer o acesso a medicamentos de interesse em saúde pública de alto custo ou protegidos por patentes, dentro das quais estão as negociações centralizadas de preços; o apoio financeiro público à pesquisa, desenvolvimento e produção nacional de medicamentos genéricos; a aplicação das flexibilidades do acordo sobre &#8220;Aspectos dos direitos de propriedade intelectual relacionados ao comércio&#8221; e a implementação de programas de assistência.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Accesibilidad a los servicios de salud]]></kwd>
<kwd lng="es"><![CDATA[política de la salud]]></kwd>
<kwd lng="es"><![CDATA[medicamento]]></kwd>
<kwd lng="es"><![CDATA[propiedad intelectual]]></kwd>
<kwd lng="es"><![CDATA[precio de medicamento]]></kwd>
<kwd lng="en"><![CDATA[Accessibility to health services]]></kwd>
<kwd lng="en"><![CDATA[health policy]]></kwd>
<kwd lng="en"><![CDATA[medicine]]></kwd>
<kwd lng="en"><![CDATA[intellectual property]]></kwd>
<kwd lng="en"><![CDATA[medicine price]]></kwd>
<kwd lng="pt"><![CDATA[Acessibilidade aos serviços de saúde]]></kwd>
<kwd lng="pt"><![CDATA[política de saúde]]></kwd>
<kwd lng="pt"><![CDATA[medicamento]]></kwd>
<kwd lng="pt"><![CDATA[propriedade intelectual]]></kwd>
<kwd lng="pt"><![CDATA[preço de medicamento]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="confpro">
<collab>World Health Organization</collab>
<source><![CDATA[WHA28.66 Sustancias profilácticas y terapéuticas]]></source>
<year></year>
<conf-name><![CDATA[ 28Asamblea Mundial de la Salud]]></conf-name>
<conf-date>1975</conf-date>
<conf-loc> </conf-loc>
</nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bigdeli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Tomson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Access to medicines from a health system perspective]]></article-title>
<source><![CDATA[Health Policy Plan]]></source>
<year>2013</year>
<volume>28</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>692-704</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giedion]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Bitrán]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Tristao]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Planes de beneficios en salud de América Latina. Una comparación regional]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[Inter-American Development Bank, Social Protection and Health Division]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="">
<collab>United Nations</collab>
<source><![CDATA[Final Report. The United Nations Secretary-General&#8217;s High-Level Panel on Access to Medicines]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[Monitoring Health for the SDGs. Sustainable Development Goals]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[The World Medicines Situation Report]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Olaya]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Resistencia a los medicamentos antirretrovirales en pacientes que reciben tratamiento para VIH-sida en Colombia]]></article-title>
<source><![CDATA[Infectio]]></source>
<year>2010</year>
<volume>14</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>248-57</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="book">
<collab>Management Sciences for Health</collab>
<source><![CDATA[MDS-3: Managing Access to Medicines and Health Technologies]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Arlington, VA ]]></publisher-loc>
<publisher-name><![CDATA[Management Sciences for Healt]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="">
<collab>Colombia</collab>
<collab>Consejo Nacional de Política Económica y Social</collab>
<source><![CDATA[Política Farmacéutica Nacional]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="">
<collab>Colombia</collab>
<collab>Ministerio de Salud y Protección Social</collab>
<collab>Dirección de Regulación de Beneficios, Costos y Tarifas del Aseguramiento en Salud</collab>
<source><![CDATA[Comparación entre el listado de medicamentos esenciales de la OMS número 19 y el listado de medicamentos cubiertos por el Plan de Beneficios en Salud con cargo a la Unidad de Pago por Capitación definido mediante Resolución 5592 de 2015]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Machado Alba]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Moncada Escobar]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolución del consumo de medicamentos de alto costo en Colombia]]></article-title>
<source><![CDATA[Rev Panam Salud Pública]]></source>
<year>2012</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>283-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reveiz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chapman]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Litigios por derecho a la salud en tres países de América Latina: revisión sistemática de la literatura]]></article-title>
<source><![CDATA[Rev Panam Salud Pública]]></source>
<year>2013</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>213-22</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Declaración de Doha]]></source>
<year>2001</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gentile]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Maraolo]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Niola]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Limiting the access to direct-acting antivirals against HCV: An ethical dilemma]]></article-title>
<source><![CDATA[Expert Rev Gastroenterol Hepatol]]></source>
<year>2016</year>
<volume>10</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1227-34</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pashkov]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
<name>
<surname><![CDATA[Golovanova]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Olefir]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The impact of the legal regime of intellectual property protection in the pharmaceutical market]]></article-title>
<source><![CDATA[Wiad Lek]]></source>
<year>2016</year>
<volume>69</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>582-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wirtz]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[WA]]></given-names>
</name>
<name>
<surname><![CDATA[Kwan]]></surname>
<given-names><![CDATA[GF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Access to medications for cardiovascular diseases in low- and middle-income countries]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2016</year>
<volume>133</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2076-85</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kishore]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Kolappa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jarvis]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overcoming obstacles to enable access to medicines for noncommunicable diseases in poor countries]]></article-title>
<source><![CDATA[Health Aff (Millwood)]]></source>
<year>2015</year>
<volume>34</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1569-77</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trooskin]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kostman]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Access to costly new hepatitis C drugs: Medicine, money, and advocacy]]></article-title>
<source><![CDATA[Clin Infect Dis]]></source>
<year>2015</year>
<volume>61</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1825-30</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hutchinson]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dillon]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland&#8217;s experience]]></article-title>
<source><![CDATA[Int J Drug Policy]]></source>
<year>2015</year>
<volume>26</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>1041-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoffman]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[So]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Galappat i]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing 15 proposals for promoting innovation and access to medicines globally]]></article-title>
<source><![CDATA[Ann Glob Health]]></source>
<year>2014</year>
<volume>80</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>432-43</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dylst]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Vulto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Simoens]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Societal value of generic medicines beyond cost-saving through reduced prices]]></article-title>
<source><![CDATA[Expert Rev Pharmacoecon Outcomes Res]]></source>
<year>2015</year>
<volume>15</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>701-11</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinheiro E dos]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brüning]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Macedo]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Production of antiretroviral drugs in middle- and low-income countries]]></article-title>
<source><![CDATA[Antivir Ther]]></source>
<year>2014</year>
<volume>19</volume>
<numero>Suppl 3</numero>
<issue>Suppl 3</issue>
<page-range>49-55</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pascual]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intellectual property rights, market competition and access to affordable antiretrovirals]]></article-title>
<source><![CDATA[Antivir Ther]]></source>
<year>2014</year>
<volume>19</volume>
<numero>Suppl 3</numero>
<issue>Suppl 3</issue>
<page-range>57-67</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changes to intellectual property policy in South Africa: Putting a stop to evergreening?]]></article-title>
<source><![CDATA[Expert Opin Ther Pat]]></source>
<year>2014</year>
<volume>24</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>839-43</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lemoine]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Thursz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatitis C, a global issue: Access to care and new therapeutic and preventive approaches in resource-constrained areas]]></article-title>
<source><![CDATA[Semin Liver Dis]]></source>
<year>2014</year>
<volume>34</volume>
<numero>01</numero>
<issue>01</issue>
<page-range>089-97</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kredo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Adeniyi]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Decentralising HIV treatment in lower- and middle-income countries]]></article-title>
<collab>The Cochrane Collaboration</collab>
<source><![CDATA[Cochrane Database of Systematic Reviews]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Chichester, UK ]]></publisher-loc>
<publisher-name><![CDATA[John Wiley &amp; Sons, Ltd]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatitis C treatment access and uptake for people who inject drugs: A review mapping the role of social factors]]></article-title>
<source><![CDATA[Harm Reduct J]]></source>
<year>2013</year>
<volume>10</volume>
<page-range>7</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<collab>The Lancet Oncology</collab>
<article-title xml:lang=""><![CDATA[Is India ready to lead the battle for fair access to medicines?]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2013</year>
<volume>14</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>437</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hogerzeil]]></surname>
<given-names><![CDATA[HV]]></given-names>
</name>
<name>
<surname><![CDATA[Liberman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wirtz]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Promotion of access to essential medicines for non-communicable diseases: Practical implications of the UN political declaration]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2013</year>
<volume>381</volume>
<numero>9867</numero>
<issue>9867</issue>
<page-range>680-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valverde]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Reed]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Schulman]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proposed &#8220;grant-and-access&#8221; program with price caps could stimulate development of drugs for very rare diseases]]></article-title>
<source><![CDATA[Health Aff (Millwood)]]></source>
<year>2012</year>
<volume>31</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>2528-35</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Westley]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Schwarz]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Emergency contraception: Global challenges, new opportunities]]></article-title>
<source><![CDATA[Contraception]]></source>
<year>2012</year>
<volume>85</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>429-31</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chaves]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Hasenclever]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Osorio-de-Castro]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Strategies for price reduction of HIV medicines under a monopoly situation in Brazil]]></article-title>
<source><![CDATA[Rev Saúde Pública]]></source>
<year>2015</year>
<volume>49</volume>
<numero>0</numero>
<issue>0</issue>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33.</label><nlm-citation citation-type="">
<collab>Congreso de la República de Colombia</collab>
<source><![CDATA[Ley 1753 de 2015. Plan Nacional de Desarrollo]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[Essential medicines]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="">
<collab>Colombia</collab>
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Resolución 1692, por la cual se establecen los criterios para la compra centralizada, distribución y suministro de medicamentos para la hepatitis C crónica y el seguimiento a los pacientes diagnosticados con dicha patología y se dictan otras disposiciones]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36.</label><nlm-citation citation-type="">
<collab>Colombia</collab>
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Medicamentos contra hepatitis C, ahora 80% más baratos]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B37">
<label>37.</label><nlm-citation citation-type="">
<collab>Consultor Salud</collab>
<source><![CDATA[Así quedaría control de precio de medicamentos]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B38">
<label>38.</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[Acuerdo sobre los aspectos de los derechos de propiedad intelectual relacionados con el comercio]]></source>
<year>1995</year>
</nlm-citation>
</ref>
<ref id="B39">
<label>39.</label><nlm-citation citation-type="">
<collab>Comisión de la Comunidad Andina</collab>
<source><![CDATA[Decisión 486 de 2000]]></source>
<year>2000</year>
</nlm-citation>
</ref>
<ref id="B40">
<label>40.</label><nlm-citation citation-type="">
<collab>Colombia</collab>
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Resolución 2475, por medio de la cual se adelanta una declaratoria de existencia de razones de interés público]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B41">
<label>41.</label><nlm-citation citation-type="">
<collab>Colombia</collab>
<collab>Ministerio de Salud y Protección Social</collab>
<collab>Dirección de Prestación de Servicios y Atención Primaria</collab>
<source><![CDATA[Línea base de telemedicina en municipios priorizados - Colombia. Resultados generales]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B42">
<label>42.</label><nlm-citation citation-type="">
<collab>Colombia</collab>
<collab>Ministerio de Salud y Protección Social</collab>
<source><![CDATA[Política de Atención Integral en Salud. Bogotá, Colombia]]></source>
<year>2016</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
